HSP90 and HSP7Chaperone Proteins and Interactors in Cellular Signal Transduction

$897,836ZIAFY2023CANIH

Division Of Clinical Sciences - Nci

Investigators

Linked publications & trials

Paper 38878853 Paper 38316354 Paper 37091547 Paper 36602710 Paper 35883436 Paper 35754026 Paper 35108506 Paper 35060082 Paper 34675120 Paper 34376581 Paper 33764710 Paper 33428418 Paper 32022992 Paper 31987035 Paper 30931649 Paper 30645757 Paper 29725069 Paper 29392504 Paper 29203712 Paper 29177649 Paper 28845424 Paper 27770043 Paper 27466407 Paper 27300428 Paper 27297784 Paper 27072697 Paper 26916002 Paper 26916000 Paper 26517842 Paper 26286886 Paper 26071189 Paper 26070366 Paper 26058814 Paper 25686391 Paper 24731398 Paper 24714774 Paper 24462205 Paper 24379398 Paper 24121490 Paper 24035283 Paper 23734688 Paper 23564345 Paper 23457505 Paper 23371049 Paper 23352416 Paper 23042933 Paper 22935698 Paper 22920906 Paper 22894668 Paper 22804236 Paper 22753480 Paper 22727666 Paper 22510516 Paper 22315411 Paper 22310230 Paper 22215907 Paper 22134243 Paper 22102915 Paper 21964864 Paper 21946277 Paper 21907917 Paper 21856339 Paper 21777805 Paper 21730179 Paper 21419342 Paper 21154128 Paper 21129982 Paper 21127511 Paper 20651736 Paper 20572190 Paper 20519952 Paper 20159553 Paper 20061796 Paper 19945858 Paper 19933325 Paper 19838189 Paper 19763143 Paper 19519207 Paper 19502802 Paper 19414312 Paper 19359180 Paper 19259122 Paper 19229106 Paper 19064253 Paper 18922470 Paper 18840695 Paper 18769157 Paper 18677112 Paper 18637013 Paper 18549799 Paper 18435518 Paper 18320023 Paper 17968312 Paper 17949810 Paper 17851558 Paper 17712310 Paper 17707057 Paper 17645779 Paper 17536171 Paper 17525527

Abstract

We confirmed that alternatively spliced androgen receptor (lacking ligand binding domain with which Hsp90 interacts) interacts with and remains dependent on Hsp40 and Hsp70 for stability and transcriptional activity. Further, we showed that targeting the Hsp40/Hsp70 chaperone axis is a novel strategy to treat castration-resistant prostate cancer that has become resistant to standard ant-iandrogen therapy. (2) We identified a multichaperone complex in mitochondria comprised of Trap1, Hsp60 and mitochondrial Hsp70 as a regulator of oxidative phosphorylation and ATP synthase-mediated ATP production. Assembly of the multichaperone complex is sensitive to mitochondrial ATP level. We identified multiple subunits of ATP synthase and numerous electron transport chain components as Trap1 interactors (potential clients), and we demonstrated that Trap1 knockout leads to increased oxidative phosphorylation and a strong preference for glutamine as the primary carbon source for the TCA cycle. (3) We also demonstrated that Hsp70 inhibition blocked both heat-induced and Hsp90 inhibitor-potentiated HSF1 activation and transcriptional activity by causing the destabilization of HSF1. We showed that Hsp70 bound to both HSF1 monomers (inactive) and trimers (active). confirmed in vitro and in vivo activity of Hsp70 inhibitor on castrate resistant prostate, but demonstrated an early and profound effect on mitochondrial protein translation which leads to disruption of electron transport chain (ETC) complex I, with resultant collapse of the ETC. This outcome is phenocopied by a specific inhibitor of complex I. In both cases, disruption of mitochondrial respiration restores sensitivity to enzalutamide as long as residual wild type androgen is present. In vitro effects are reproducible in vivo and can be non-invasively imaged with hyperpolarized pyruvate MR spectroscopy (HP-MRSI).

View original record on NIH RePORTER →